what this node claims
AlphaFold metrics / FOXO3
Model-quality receipt for the fold. It is not biological validation.
vertical proof spine
evidence / risk instrument
48%
low debt pressure
24%
51%structurethin
pLDDT 50.66
78%evidenceusable
grade B
0%gatesdebt
0/5 gates
100%riskstrong
0 hard flags
22%exportdebt
no export
33%lineagedebt
incomplete spine
proof completeness
33% missing target, candidate, finding, export- 01 target
- 02 fold
- 03 alphafold metric
- 04 candidate
- 05 finding
- 06 export
Metrics and receipt inputs
- confidence band
- low
- confidence pct
- 50.66
- coverage context
- missing or not linked
- interpretation
- weak structural context; downstream claims should be conservative
- pae context
- missing or not linked
- plddt avg
- 50.66
- sequence length
- 0
AlphaFold metrics visual
Low-confidence regions present
673 residues / min 30.38 / max 97.69 / source alphafold db
Very high
9.2%
62 residues / >=90
Confident
4.2%
28 residues / 70-89
Low
17.5%
118 residues / 50-69
Very low
69.1%
465 residues / <50
weak structural context; downstream claims should be conservative
Near-complete coverage / observed 673 of 673 residues.
- residues 240-622 / mean 43.05
- residues 1-153 / mean 47.37
- residues 630-673 / mean 45.99
- residues 201-202 / mean 64.41
proof debt register
24%
Visible limits, not hidden cleanup.
Peptide RX keeps unresolved proof debt attached to the public receipt. Some debts should be resolved; redaction and research-use boundaries should stay visible.